Welcome to our dedicated page for Esperion Therapeutics news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therapeutics stock.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a leading pharmaceutical company specializing in the development and commercialization of innovative, first-in-class, oral therapies aimed at lowering low-density lipoprotein cholesterol (LDL-C). The company's flagship product, ETC-1002, is a potent inhibitor of ATP citrate lyase, an enzyme integral to the cholesterol biosynthesis pathway. This pathway also includes HMG-CoA reductase, the enzyme targeted by statins.
Esperion has made significant progress with ETC-1002, completing Phase 1 and Phase 2 clinical trials, and is set to initiate Phase 3 trials. The company's product lineup includes NEXLETOL and NEXLIZET, both of which are oral, once-daily, non-statin medications designed to tackle elevated LDL-C levels. These drugs have recently received expanded FDA approval for cardiovascular risk reduction and are indicated for both primary and secondary prevention patients.
In recent news, Esperion announced that both NEXLETOL and NEXLIZET have received broad new label expansions. These labels now cover cardiovascular risk reduction and expanded LDL-C lowering, either alone or in combination with statins. This approval allows over 70 million patients to access these life-saving drugs, positioning them as the non-statin drugs of choice for cardiovascular risk management.
Esperion is also ramping up its marketing and promotional efforts, enhancing patient support programs, and working with payers to improve patient access. The company is committed to breaking barriers in cardiovascular care and continues to focus on underserved populations, including women and Hispanic/Latinx patients, as demonstrated by their recent CLEAR Outcomes trial.
The company's forward-looking strategy includes ongoing clinical development, financial management, and expansion into new markets. Esperion's dedication to transforming cardiovascular care is evident in its robust pipeline and strategic initiatives aimed at addressing critical unmet medical needs.
Esperion (NASDAQ: ESPR) will announce its fourth quarter and full year 2022 financial results on February 21, 2023, before U.S. market open. Following the announcement, management will host a webcast and conference call at 8:00 a.m. ET to discuss the results and upcoming milestones. Investors can pre-register for the call and access a live webcast on the company’s investor section. The replay will be available shortly after the call and archived for 90 days. Esperion focuses on developing innovative cholesterol-lowering therapies, aiming to provide solutions for patients with unmet needs.
Esperion Therapeutics has secured a multi-year partnership with RFK Racing, which will see its cholesterol-lowering treatments, NEXLIZET and NEXLETOL, showcased in the upcoming NASCAR season.
NEXLIZET will debut on Brad Keselowski's No. 6 Ford during the Daytona 500 on February 19, while NEXLETOL will be featured on Chris Buescher's No. 17 Ford throughout the season.
Esperion aims to raise brand awareness and educate consumers on cardiovascular health through this collaboration.
Esperion (NASDAQ: ESPR) reported preliminary Q4 2022 U.S. net product revenue between $14.4 million and $15.1 million, reflecting a 38%-40% year-over-year growth. The company anticipates global regulatory submissions based on robust CLEAR Outcomes data in 1H 2023, potentially leading to milestone payments upon approvals. Esperion has also partnered with RFK Racing to boost brand awareness and engage with a wider audience. The firm aims to enhance cardiovascular outcomes through its bempedoic acid franchise, targeting patients struggling with LDL cholesterol management.
Esperion (NASDAQ: ESPR) announced that their CLEAR Outcomes trial will present positive results at the ACC.23/WCC conference on March 4, 2023. Bempedoic acid, an oral non-statin drug, is the first ATP citrate lyase inhibitor to meet the MACE-4 primary endpoint, showcasing its potential to reduce LDL-C and cardiovascular risks for patients intolerant to statins. The trial involved over 14,000 patients across 32 countries, highlighting significant clinical impact amidst recent unsuccessful studies. Esperion anticipates strong interest from healthcare providers.
Esperion announced on December 9, 2022, the granting of 5,600 restricted stock units (RSUs) to two new employees under its 2017 Inducement Equity Incentive Plan. This plan is designed for individuals who are new hires and was established in accordance with NASDAQ Listing Rules. The RSUs will vest over a four-year period, with 25% vesting on the one-year anniversary of the grant and the remaining 75% vesting quarterly thereafter, contingent on continued employment. Esperion focuses on developing innovative cholesterol-lowering therapies.
Esperion (NASDAQ: ESPR) will present at two significant healthcare events: the J.P. Morgan 41st Annual Healthcare Conference and the LifeSci Partners 12th Annual Corporate Access Event, from January 9-11, 2023, in San Francisco, California.
At the J.P. Morgan Conference, CEO Sheldon Koenig will present and engage in 1x1 investor meetings on January 11 at 1:30 PM PT. The LifeSci event will also feature Koenig along with CFO Ben Halladay and CMO JoAnne Foody hosting investor meetings on January 9-10.
Esperion announced that its CLEAR Outcomes trial for bempedoic acid successfully met its primary endpoint. The trial demonstrated a statistically significant reduction in major adverse cardiovascular events (MACE-4) among patients treated with 180 mg/day of NEXLETOL compared to placebo. This makes bempedoic acid the first ATP citrate lyase inhibitor to achieve such results. The study involved over 14,000 patients across 32 countries, addressing the need for effective treatments in patients unable to tolerate statins. Comprehensive data will be presented at a key medical conference in early 2023.
Esperion (NASDAQ: ESPR) announced the promotion of Ben Halladay, MBA, to Chief Financial Officer (CFO), effective immediately. Previously serving as Senior Director of Financial Planning and Analysis, Halladay has been integral to the company's finance team since joining in 2020. CEO Sheldon Koenig expressed confidence in Halladay's leadership amidst a transitional phase for the company, particularly with the impending CLEAR Outcomes study results. Halladay brings extensive finance experience from roles at National Oilwell Varco, BMC Software, and Pfizer, which positions him to contribute significantly to Esperion's future success.
Esperion (NASDAQ: ESPR) hosted a virtual R&D Day on November 9, 2022, showcasing discussions on cardiovascular disease treatments by renowned experts. The event highlighted the company’s investigational pipeline, focusing on the CLEAR Outcomes study, which assesses the effectiveness of NEXLETOL in reducing cardiovascular events in statin-intolerant patients. With over 14,000 participants, this Phase 3 trial completed its primary event target in August 2022, positioning Esperion for significant growth in future cardiovascular therapies.
Esperion (NASDAQ: ESPR) announced that President and CEO, Sheldon Koenig, will present at the Jefferies London Healthcare Conference on November 16, 2022, at 5:20 AM (EST). The presentation will include a live audio webcast, accessible via the company's website, with a replay available approximately two hours post-event. Esperion is dedicated to developing innovative medications aimed at lowering cholesterol, especially for patients with unmet needs. For further details, visit www.esperion.com.
FAQ
What is the current stock price of Esperion Therapeutics (ESPR)?
What is the market cap of Esperion Therapeutics (ESPR)?
What is Esperion Therapeutics, Inc.?
What products does Esperion offer?
What recent achievements has Esperion made?
What is ETC-1002?
What is the significance of the CLEAR Outcomes trial?
Who can benefit from Esperion's medications?
What partnerships does Esperion have?
What are the common side effects of NEXLETOL and NEXLIZET?
How does Esperion support its patients?
What are Esperion's future plans?
